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Abstract
The Contraceptive CHOICE Project (CHOICE) sought to reduce unintended pregnancies in the St. Louis
Region by removing cost, education, and access barriers to highly effective contraception. CHOICE was a
prospective cohort study of over 9,000 women 14–45 years of age who received tiered contraceptive counseling
to increase awareness of all reversible methods available, particularly long-acting reversible contraceptive
(LARC) methods. Participants were provided with contraception of their choice at no cost for 2–3 years. We
studied contraceptive method choice, continuation, and population outcomes of repeat abortion and teen
pregnancy. Seventy-five percent of study participants chose one of the three LARC methods (46% levo-
norgestrel intrauterine system, 12% copper intrauterine device, and 17% subdermal implant). LARC users
reported greater continuation than non-LARC users at 12 months (87% versus 57%) and 24 months (77% versus
41%). In our cohort, LARC methods were 20 times more effective than non-LARC methods. As a result, we
observed a reduction in the percent of repeat abortions from 2006 to 2010 in St. Louis compared with Kansas
City and nonmetropolitan Missouri and found substantial reductions in teen pregnancy, birth, and abortion
(34.0, 19.4, and 9.7 per 1000 teens, respectively) compared with national rates among sexually experienced
teens (158.5, 94.0, and 41.5 per 1000, respectively). Improved access to LARC methods can result in fewer
unintended pregnancies and abortions and considerable cost savings to the health care system.
Introduction
Among all pregnancies in the United States, 51% areunintended, and 40% of unintended pregnancies result
in induced abortions.1 Effective family planning could pre-
vent as many as one in every three maternal deaths globally
by delaying motherhood, spacing births, avoiding unintended
pregnancies and abortions, and allowing women to stop
childbearing when they have reached their desired family
size.2–4
Unlike the oral contraceptive pill or injection, long-acting
reversible contraceptive (LARC) methods, such as the in-
trauterine device (IUD) and subdermal implant, are designed
so that once inserted, a woman does not have to think about
using birth control on a daily, weekly, monthly or quarterly
basis. Women who use LARC methods experience effec-
tiveness rates of greater than 99%; perfect and typical use
effective rates are equivalent. Despite the availability of
LARC, less than 8% of women in the United States use an
IUD and even fewer report use of the subdermal implant.5
Women and teens experience multiple barriers when acces-
sing and using birth control including prohibitive method
costs, limited or nonexistent information about all methods
available, and provider bias or outdated clinical practice re-
garding appropriate candidates for particular contraceptive
methods.6–10
The Contraceptive CHOICE Project was launched to
promote the use of long-acting, reversible contraception to
reduce the number of unintended pregnancies in the St. Louis
region. The project removed three key barriers to use of
LARC methods: cost, education, and access. The objective of
this report is to provide an overview of the key findings of
CHOICE once the three barriers were removed for 9,256
St. Louis-area women and teens.
Methods
The CHOICE Project was an observational cohort study
that provided each participant with the reversible contra-
ception of her choice at no cost for 2–3 years. The CHOICE
protocol was approved by the Washington University in St.
Louis School of Medicine Human Research Protection
Department of Obstetrics and Gynecology, Division of Clinical Research, Washington University in St. Louis School of Medicine,
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Office before participant recruitment began. Women were
eligible to participate if they (1) were 14–45 years of age;
(2) resided in the St. Louis region; (3) were English or
Spanish speaking; (4) were interested in reversible contra-
ception; (5) were sexually active with a male partner in the
past 6 months or anticipated sexual activity in the next 6
months; (6) did not desire pregnancy in the next year; and
(7) were not currently using a contraceptive method or in-
terested in starting a new reversible contraceptive method.
Between August 2007 and September 2011, participants
were recruited through convenience sampling at 13 recruit-
ment sites that included university-affiliated clinics and
providers, two facilities providing abortions services, and
community clinics providing family planning, obstetric, gy-
necologic, and primary care. Participants received standard-
ized tiered contraceptive counseling by trained counselors
who presented the contraceptive methods from most to least
effective and briefly reviewed the risks, benefits, and com-
mon side effects of each method.11 Because none of the
methods prevent sexually transmitted infections (STIs),
counselors also discussed condom use during each counsel-
ing session, and participants were provided with free con-
doms. After contraceptive counseling and written informed
consent, participants completed a baseline survey and were
screened for STIs. A brief medical history was performed to
rule out medical contraindications to specific contraceptive
methods. Participants then received their contraceptive
method of choice at no cost and could change their method at
any time during the study participation. Study staff were
trained to provide timely and accurate responses to participant
questions or concerns regarding method use throughout the
study. Staff-administered telephone interviews were con-
ducted at 3 and 6 months, and at every 6 months post-
enrollment for the duration of study participation. We collected
data regarding method continuation, satisfaction, side effects,
sexual behaviors (e.g., number of male sexual partners and
coital frequency during the previous 30 days), change in re-
productive plans (e.g., desire to conceive), and unintended
pregnancy.
In this review, we summarize our key findings regarding
method continuation, method effectiveness/failure rates, pop-
ulation outcomes (i.e., percentage of abortions that were repeat
abortions as well as teen pregnancy rates), and the change in
LARC use at select partner clinics in the St. Louis area.
Results
Seventy-five percent of CHOICE participants chose one of
the three LARC methods (46% levonorgestrel intrauterine
system, 12% copper IUD, and 17% subdermal implant).12
Greater LARC uptake was observed in women over 25 years
of age (79%) compared with younger women 14–25 years
(69%).13 Among the youngest participants, the selection of
LARC method varied by age; 14- to17-year-old LARC users
preferred the subdermal implant (64.5%), and 18- to 20-year-
old LARC users preferred the IUD (61.4%).14
Figure 1 presents continuation data by contraceptive
method. LARC users reported higher continuation than users
of non-LARC methods at both 12 months (87% vs. 57%) and
24 months (77% vs. 41%).15 Among teen participants aged
14–19 years, 82% of LARC users were using their method at
12 months compared with 49% of non-LARC users. The same
pattern was observed at 24 months: 67% of teen LARC users
compared with 37% of teen non-LARC users were using their
method at 2 years. Among the entire cohort of LARC users in
the CHOICE Project, 7% reported discontinuation within the
first 6 months of use.16 We found no difference in early LARC
discontinuation between teens aged 14–19 and women 20
years and older (8.5% vs. 7.1%, p = 0.72).
Greater LARC uptake in our population did not result in
greater sexual risk behavior (i.e., increased number of sexual
partners). We found that 71% of study participants reported
no change in the number of sexual partners at 12 months
compared with baseline, and only 16% reported an increase.17
Of those reporting an increase in sexual partners, more than
80% reported a change from zero partners to one partner.
The difference in effectiveness between LARC methods and
combined hormonal contraceptive methods (oral contraceptive
FIG. 1. Twelve- and twenty-
four-month continuation by con-
traceptive method. IUD, intrauter-
ine device; LARC, long-acting
reversible contraceptive; LNG-
IUS, levonorgestrel intrauterine
system; OCP, oral contraceptive pill.
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pills, contraceptive patch, and vaginal ring) was remarkable.
The cumulative contraceptive failure rates at 1, 2, and 3 years
for the pills, patch, and ring (4.8%, 7.8%, and 9.4%) were more
than 20 times higher than for the LARC methods (0.3%, 0.6%,
and 0.9%; adjusted hazard ratio= 21.8, 95% confidence inter-
val 13.7–34.9; Fig. 2).18
With respect to repeat abortion rates, we conducted an
ecological analysis that compared the St. Louis region to the
Kansas City region because they are similar in size and de-
mographic profile. We observed a significant decrease
( p = 0.002) in the percent of repeat abortions from 2006 to
2010 in St. Louis compared with a significant increase
( p = 0.003) in Kansas City.12 Our analysis of teen pregnancy,
birth, and abortion rates demonstrated a substantial reduction
in rates observed in our cohort compared with national rates
among sexually experienced teens. The average annual rates
of pregnancy, birth, and abortion among CHOICE teen par-
ticipants were 34.0, 19.4, and 9.7 per 1000 teens, respec-
tively. In comparison, rates of pregnancy, birth, and abortion
among sexually experienced U.S. teens in 2008 were 158.5,
94.0, and 41.5 per 1000, respectively.14
Finally, we obtained contraceptive method use data from
two Title X-funded family planning clinics in our area that had
partnered with CHOICE to observe the clinic-level change in
LARC use from 2006 to 2013. IUD use increased from 3% to
12% and from 0% to 4% among the two clinics. Subdermal
implant use increased from 0% to 5% and 0% to 3% (Fig. 3).
Discussion
The results of the Contraceptive CHOICE Project indicate
several ways to address the significant public health concern
posed by unintended pregnancies. In CHOICE, we found that
when we removed access barriers, cost barriers, and provided
women with comprehensive, accurate, unbiased counseling,
women preferred the subdermal implant and IUDs: the most
effective, reversible contraceptive methods.19 We found that
women using LARC methods continue use at a higher rate
than women using shorter-acting methods.13,15,20
Overall, the Contraceptive CHOICE Project demonstrated
a shift in method use from less to more effective methods,
which could provide powerful protection against teen and
FIG. 2. Cumulative failure rates
at 1, 2, and 3 years for LARC
and non-LARC methods.
FIG. 3. Change in LARC use
from 2006 to 2013 in two St. Louis
family planning clinics.
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unintended pregnancies.12 Furthermore, the three LARC
methods are among the most cost-effective forms of contra-
ception.21 In addition, we did not find an increase in risky
sexual behavior or more STIs with increased LARC use.17
Thus, increased utilization of LARC methods is an important
strategy to reduce unintended pregnancies, which would both
improve women’s health and save health care dollars.22
The CHOICE Project provided a model of contraceptive
provision that was unique but adaptable. All women received
tiered contraceptive counseling by a trained counselor and
were informed that LARC methods are the most effective
reversible methods of contraception.11 Cost barriers were
removed; all methods were provided at no cost to partici-
pants. Finally, access was increased; providers were willing
to provide LARC methods to almost all women, regardless of
parity, young age, or STI risk factors. In fact, the majority of
LARC methods were provided on the same day as enrollment
(same-day insertion). A randomized, controlled trial of a
4-hour LARC training program regarding LARC counseling
and clinical practice to clinic staff at 40 Planned Parenthood
locations showed that women in the intervention group were
twice as likely to choose a LARC method than those in the
control group.23 The LARC uptake observed in CHOICE was
greater than that observed in this study, suggesting the im-
portance of addressing all three barriers of cost, education,
and access. Furthermore, the doubling of LARC use in the
two Title X clinics where the CHOICE model was available
to clinic patients provides encouraging evidence to support
the integration of the model in the Title X setting.
Conclusion
The CHOICE Project developed and provided a high level
of contraceptive care where barriers to greater LARC use
were removed, and ongoing care to maximize method con-
tinuation was prioritized through close patient follow-up and
responsiveness to participants’ concerns and side effects. We
believe this model of care, where the entire clinic prioritizes
effective family planning and promotes LARC use, can be
disseminated and implemented in a variety of settings. Im-
plementation requires training of all staff, including front
desk, clinical, management, and finance to ensure that af-
fordable LARC methods are available, the most up-to-date
clinical practices are documented and integrated into care,
and that women hear accurate and unbiased information re-
garding contraception throughout their clinic experience. In
response, CHOICE has catalogued the research findings,
training protocols, and patient care materials used throughout
the project to encourage their use by others. These materials
can be found at www.CHOICEProject.wustl.edu and
www.LARCFIRST.com. If successful, diffusion of the
CHOICE approach may finally help reduce the number of
unintended pregnancies in the United States.
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